<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">USH2A Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>USH2A</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>USH2A</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=USH2A" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">USH2A Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>USH2A</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>USH2A</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=USH2A" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
USH2A encodes usherin, a large transmembrane protein that belongs to the usherin family containing fibronectin type III domains and laminin G-like domains. Usherin is critical for the development and maintenance of photoreceptor cells and hair cells in the inner ear. Mutations in USH2A are the most common cause of Usher syndrome type II, a condition causing both hearing loss and visual impairment. Recent studies have also identified USH2A variants as risk factors for Parkinson's disease, suggesting roles in neuronal function beyond the sensory systems. [@yan2010]
Usherin is an exceptionally large protein composed of approximately 5,600 amino acids with a molecular weight of around 171 kDa. The protein undergoes extensive post-translational modifications including glycosylation that are essential for its proper function and localization. The complexity of USH2A structure reflects its diverse functional roles in multiple tissues. [@sahly2012]
Usherin is a large protein containing multiple distinct domains. The N-terminal signal peptide directs the protein to the secretory pathway. The extracellular region contains numerous fibronectin type III domains that mediate protein-protein interactions. Laminin G-like domains are present and involved in binding to other extracellular matrix components. A transmembrane domain anchors the protein in cellular membranes. The intracellular domain contains motifs that interact with the cytoskeleton and signaling proteins. [@panagiotou2023]
Multiple isoforms of USH2A are expressed in different tissues. The full-length isoform (usherin) is primarily expressed in photoreceptors and inner ear hair cells. Shorter isoforms may have tissue-specific functions. Alternative splicing contributes to isoform diversity. These isoforms may have distinct subcellular localizations and functions. [@gelfman2022]
Usherin undergoes extensive post-translational modifications. N-linked glycosylation occurs at multiple sites and is essential for proper folding and function. The protein is secreted and incorporated into the extracellular matrix. Proteolytic processing may generate functional fragments. These modifications are crucial for protein stability and activity. [@pierpont2000]
In the retina, usherin plays essential roles in photoreceptor cell health and function. The protein localizes to the photoreceptor outer segments where it participates in disc membrane maintenance. Usherin interacts with other proteins involved in phototransduction. The protein is important for photoreceptor cell survival and function. [@sorusor2023]
In the cochlea, usherin is critical for hair cell development and function. The protein localizes to stereocilia, the hair cell mechanosensitive organelles. Usherin participates in the development and maintenance of stereocilia structure. The protein is essential for normal hearing. Mutations cause progressive hearing loss. [@yoshik2022]
Usherin interacts with various extracellular matrix components. These interactions are important for tissue structure and function. The protein binds to laminin and other matrix proteins. These interactions contribute to cell-matrix adhesion and signaling. [@blain2023]
USH2A mutations are the most common cause of Usher syndrome type II, a recessive disorder characterized by hearing loss and retinitis pigmentosa. The syndrome typically presents with progressive hearing loss from birth and vision loss beginning in adolescence or early adulthood. The disease affects both photoreceptors and hair cells, reflecting the expression pattern of USH2A. [@fu2024]
In retinitis pigmentosa, USH2A mutations cause progressive photoreceptor degeneration. Patients experience tunnel vision and eventual blindness. The age of onset and rate of progression vary. Over 100 pathogenic USH2A variants have been identified. [@huang2023]
USH2A-related hearing loss is typically moderate to severe. The hearing loss is stable and does not progress significantly after childhood. Cochlear implants are effective for many patients. The diagnosis requires genetic testing for confirmation.
Recent genome-wide association studies have identified USH2A variants as risk factors for Parkinson's disease. The mechanism linking USH2A to Parkinson's disease is not yet understood. The protein may have roles in neuronal function beyond the sensory systems. This connection is an area of active investigation.
The identification of USH2A variants in Parkinson's disease suggests additional neuronal roles. The protein may be expressed in areas of the brain affected in Parkinson's disease. Potential functions include synaptic maintenance or neuronal survival. More research is needed to clarify these connections.
The USH2A gene is located on chromosome 1q41 and spans approximately 790 kb. The gene contains 72 exons encoding the large usherin protein. Multiple alternative exons allow for isoform diversity. The gene structure is complex due to its large size.
Over 100 pathogenic variants have been identified in USH2A. These include nonsense mutations, frameshifts, splice site mutations, and missense variants. Most pathogenic variants create null alleles resulting in complete loss of function. Genotype-phenotype correlations are imperfect due to variable expressivity.
Carrier frequencies for USH2A pathogenic variants vary by population. The carrier rate is approximately 1 in 70 in some populations. This makes USH2A one of the more common genetic causes of inherited blindness and deafness.
Gene therapy approaches for USH2A are under development. Viral vector delivery can restore usherin expression in animal models. Clinical trials for other inherited retinal diseases provide a roadmap. Challenges include the large gene size and photoreceptor targeting.
Small molecule therapies aim to rescue mutant usherin function. nonsense suppression therapies may benefit patients with truncating mutations. Protein folding correctors are being explored for missense variants.
Stem cell-derived retinal cells may provide replacement therapy. Clinical trials for other retinal diseases are ongoing. These approaches may eventually benefit USH2A patients.
Cochlear implants effectively restore hearing in USH2A patients. Low vision aids help with daily activities. Retinal implants are being developed for advanced disease.
Genetic testing confirms the diagnosis of USH2A-related disease. Panel testing for inherited retinal diseases and deafness includes USH2A. Whole exome sequencing can also identify pathogenic variants. Interpretation of variants of uncertain significance requires careful analysis.
Patients with Usher syndrome type II present with both hearing loss and visual problems. Audiologic testing reveals characteristic hearing loss patterns. Ophthalmologic evaluation shows signs of retinitis pigmentosa. Vestibular testing may show mild abnormalities.
Clinical biomarkers for disease progression are needed. Visual field testing and electroretinography track photoreceptor function. Audiologic testing monitors hearing. Research continues to identify new biomarkers.
Mouse models of USH2A have been developed. Knockout mice recapitulate key features of Usher syndrome. These models are used to test therapeutic approaches. Larger animal models are being developed.
Patient-derived induced pluripotent stem cells provide relevant models. Retinal organoids can model photoreceptor development. These models allow mechanistic studies and drug testing.
Protein expression and purification studies inform understanding. Interaction partners have been identified. These studies guide therapeutic development.
Usher syndrome type II accounts for approximately 50-70% of all Usher syndrome cases. The overall prevalence is approximately 1 in 25,000. USH2A mutations cause up to 20% of all autosomal recessive retinitis pigmentosa.
The disease occurs worldwide with no clear ethnic predominance. Founder mutations have been identified in some populations. Carrier screening programs exist in some regions.
The combined hearing and visual impairment in Usher syndrome creates significant disability. Early intervention improves outcomes. Assistive technologies represent a significant healthcare cost.
Multidisciplinary care is essential for Usher syndrome patients. Audiologists, ophthalmologists, and genetic counselors collaborate. Early intervention with hearing aids and vision aids is critical. Regular monitoring allows timely intervention.
Patient advocacy groups provide valuable support and information. The Foundation for Retinal Research and Usher Syndrome Coalition are key organizations. These groups fund research and provide patient resources.
With appropriate support, patients can lead productive lives. Education and vocational support are important. Assistive technology enables independence. Psychological support helps patients adapt.
Clinical trials for USH2A gene therapy are anticipated. The large gene size presents delivery challenges. Animal studies continue to refine approaches. Patient selection criteria are being developed.
Understanding USH2A function in neurons may reveal new targets. Parkinson's disease connections need clarification. Basic research continues to inform clinical development.
Disease progression biomarkers are needed for clinical trials. Visual function tests may serve as endpoints. Audiologic measures are being validated.
Genotype-specific therapies are being developed. Nonsense suppression may help patients with specific mutations. Personalized approaches will improve outcomes.
USH2A encodes usherin, a large protein essential for photoreceptor and hair cell function. Mutations cause Usher syndrome type II, the most common form of Usher syndrome. The disease causes hearing loss and progressive vision loss. Recent research has identified USH2A variants as Parkinson's disease risk factors, suggesting broader neuronal roles. Gene therapy and other treatments are in development. Early diagnosis through genetic testing enables appropriate intervention. Supportive care remains important for affected individuals. Research continues to develop effective therapies for this challenging condition.
Usherin interacts with various proteins to perform its functions. In the retina, it binds to VLGR1 (very large G-protein coupled receptor 1) at the photoreceptor synapse. This interaction is important for photoreceptor development and function. The protein also interacts with scaffold proteins that position it correctly in the cell membrane.
Usherin participates in several signaling pathways. In photoreceptors, it may be involved in phototransduction cascade signaling. In hair cells, it participates in mechanotransduction signaling. The protein may activate downstream pathways affecting cell survival.
The intracellular domain of usherin interacts with the cytoskeleton. These interactions are important for maintaining cell structure. In hair cells, these interactions are essential for stereocilia function. Disruption of cytoskeletal interactions contributes to disease.
Usherin contributes to extracellular matrix organization. The protein binds to laminin and other matrix components. This organizes the photoreceptor outer segment environment. Proper matrix organization is essential for photoreceptor function.
In photoreceptor outer segments, usherin participates in disk membrane assembly. The protein may help organize the elaborate membrane structure. This function is essential for phototransduction. Mutations affecting this process cause retinal degeneration.
Photoreceptor outer segments are highly specialized sensory structures. They contain the visual pigment molecules that capture light. The disk membranes are continuously renewed. Usherin plays a role in this renewal process.
Hair cell stereocilia are actin-based mechanosensitive organelles. They detect sound vibrations and head movements. Usherin localizes to the stereocilia tips and ankle links. These structures are essential for hearing.
Usherin undergoes complex trafficking within cells. The protein is synthesized in the cell body and transported to appropriate compartments. Proper trafficking is essential for protein function. Mutations affecting trafficking cause disease.
At the membrane, usherin organizes protein complexes. These complexes are essential for cell-cell adhesion and signaling. The organization affects photoreceptor and hair cell function.
The hearing loss in Usher syndrome type II is distinctive. It is present from birth and is stable throughout life. The loss typically affects all frequencies. Speech development is usually normal with appropriate intervention.
Retinitis pigmentosa in Usher syndrome type II typically begins in adolescence. Patients first notice night blindness. Peripheral vision loss progresses over decades. Central vision is usually retained until later stages.
Some patients with Usher syndrome type II have mild balance problems. Vestibular testing may show abnormalities. However, significant balance problems are more common in other Usher types. This helps differentiate the subtypes.
The progression of visual loss varies among patients. Some maintain useful vision into late adulthood. Others progress more rapidly. The reasons for this variability are not fully understood.
Comprehensive audiologic testing is essential for diagnosis. This includes pure tone and speech audiometry. Impedance audiometry assesses middle ear function. Auditory brainstem responses may also be evaluated.
Visual field testing reveals the characteristic peripheral field loss. Electroretinography shows reduced photoreceptor function. Optical coherence tomography assesses retinal structure. These tests track disease progression.
Genetic testing confirms the diagnosis. Panel testing for retinal dystrophies includes USH2A. Whole exome sequencing may identify rare variants. Accurate genetic diagnosis enables family counseling.
Hearing aids are effective for most patients. Cochlear implants provide benefit for those with severe loss. Communication strategies include sign language. Early intervention is essential for language development.
Low vision aids help maintain independence. Orientation and mobility training is valuable. Social support improves quality of life. Regular ophthalmologic care monitors progression.
Coordinated care from multiple specialists is essential. This includes audiologists, ophthalmologists, and genetic counselors. Teachers of the deaf and vision specialists contribute. This team approach optimizes outcomes.
The dual sensory impairment creates unique challenges. Psychological support helps patients adapt. Support groups connect patients with others facing similar challenges. Education empowers patients and families.
New viral vectors are being developed for gene therapy. The large USH2A cDNA presents delivery challenges. Novel vectors may overcome this obstacle. Research continues to optimize delivery.
Ataluren and similar drugs may help patients with nonsense mutations. These drugs allow readthrough of premature stop codons. Clinical trials for other conditions inform development. This may benefit a subset of USH2A patients.
Small molecules that correct misfolding are being explored. These drugs may rescue function for missense mutations. High-throughput screening identifies candidate compounds. This represents a precision medicine approach.
Retinal cell transplantation may restore vision. Clinical trials for other conditions are ongoing. These approaches may eventually benefit USH2A patients. Research continues to refine these methods.
Population-based carrier screening may identify at-risk couples. This enables informed reproductive decisions. The feasibility of screening is under study. Cost-effectiveness analyses are ongoing.
Newborn hearing screening identifies infants with hearing loss. This enables early diagnosis of Usher syndrome. Early intervention improves outcomes. This represents an important public health advance.
The long-term care needs of Usher syndrome patients are significant. Early intervention reduces lifetime costs. Assistive technology and support services are expensive. Healthcare policy affects access to care.
Patient advocacy groups play crucial roles. They fund research and provide support. The Usher Syndrome Coalition and Foundation for Retinal Research are key organizations. These groups advance awareness and research.
Government and private funding supports USH2A research. Progress has accelerated in recent years. Clinical trials are anticipated. This gives hope to affected individuals.
Increased clinical awareness improves diagnosis. Healthcare provider education is important. Referral to specialists ensures appropriate care. This improves outcomes for patients.
USH2A is a critical protein for photoreceptor and hair cell function. Mutations cause Usher syndrome type II, the most common form of Usher syndrome. The disease causes congenital hearing loss and progressive retinal degeneration. Recent findings link USH2A to Parkinson's disease risk. Gene therapy and other treatments are in development. Early diagnosis and intervention remain essential. Continued research offers hope for effective therapies in the future.
The following diagram shows the key molecular relationships involving USH2A Protein discovered through SciDEX knowledge graph analysis: